StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Immuneering Corporation (IMRX)

Thu, 27 Aug 2026 07:08:13 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $14.00 price target on Immuneering Corporation (NASDAQ: IMRX).

The analyst commented: "The first approval of a RAS-directed therapy in metastatic pancreatic cancer is an important milestone for the field, but we do not view it as weakening the atebimetinib thesis. If anything, we think the initial investor reaction risks are conflating two very different clinical opportunities. The newly approved therapy is positioned in second-line metastatic disease, while atebimetinib is already enrolling a global randomized Phase 3 study in previously untreated patients, where the unmet need remains considerably larger. More importantly, atebimetinib

Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug

Wed, 26 Aug 2026 17:16:26 -0400

Immuneering Corporation (Nasdaq: IMRX) responded to the FDA's approval of a new second-line treatment for metastatic pancreatic cancer, reiterating its focus on first-line patients through its ongoing Phase 3 trial, MAPKeeper 301.

MAPKeeper 301 is a global, randomized trial evaluating atebimetinib in combination with chemotherapy in patients with first-line metastatic pancreatic cancer. The trial has more than 35 locations listed on ClinicalTrials.gov and is currently enrolling patients.

Immuneering previously reported results from a Phase 2a study of atebimetinib 320 mg once daily plus modified gemcitabine/nab-paclitaxel in 55 first-line metastatic pancreatic cancer patients. As of an April 24, 2026 data cutoff, with a

Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug

Wed, 26 Aug 2026 17:16:26 -0400

Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug

Wed, 26 Aug 2026 17:16:26 -0400

Immuneering touts Phase 3 trial as FDA clears new pancreatic cancer drug

Wed, 26 Aug 2026 17:16:26 -0400

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Wed, 26 Aug 2026 17:16:00 -0400

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone –

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

- 17.3-month median overall survival previously reported from Immuneering’s Phase 2a study of atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in 1L pancreatic cancer -

- In the same Phase 2a study, the only Grade 3+ treatment-related adverse events in ≥10% of patients were anemia (16%) and neutropenia (18%), both

H.C. Wainwright Starts Immuneering Corporation (IMRX) at Buy

Thu, 06 Aug 2026 06:06:48 -0400

H.C. Wainwright analyst Andres Maldonado initiates coverage on Immuneering Corporation (NASDAQ: IMRX) with a Buy rating and a price target of $14.00.
The analyst comments "What’s new? We are initiating coverage of Immuneering (IMRX) with a Buy rating and $14 PT based on a thesis that extends well beyond the 17.3-month median OS currently driving investor attention in pancreatic cancer. MEK was never an unimportant target, but chronic MEK inhibition has historically been a poor way to drug it. Atebimetinib was designed around a fundamentally different pharmacologic strategy, termed Deep Cyclic Inhibition, or DCI, which uses a high free-drug peak to

H.C. Wainwright Starts Immuneering Corporation (IMRX) at Buy

Thu, 06 Aug 2026 06:06:48 -0400

H.C. Wainwright analyst Andres Maldonado initiates coverage on Immuneering Corporation (NASDAQ: IMRX) with a Buy rating and a price target of $14.00.
The analyst comments "What’s new? We are initiating coverage of Immuneering (IMRX) with a Buy rating and $14 PT based on a thesis that extends well beyond the 17.3-month median OS currently driving investor attention in pancreatic cancer. MEK was never an unimportant target, but chronic MEK inhibition has historically been a poor way to drug it. Atebimetinib was designed around a fundamentally different pharmacologic strategy, termed Deep Cyclic Inhibition, or DCI, which uses a high free-drug peak to

H.C. Wainwright Starts Immuneering Corporation (IMRX) at Buy

Thu, 06 Aug 2026 06:06:48 -0400

H.C. Wainwright analyst Andres Maldonado initiates coverage on Immuneering Corporation (NASDAQ: IMRX) with a Buy rating and a price target of $14.00.
The analyst comments "What’s new? We are initiating coverage of Immuneering (IMRX) with a Buy rating and $14 PT based on a thesis that extends well beyond the 17.3-month median OS currently driving investor attention in pancreatic cancer. MEK was never an unimportant target, but chronic MEK inhibition has historically been a poor way to drug it. Atebimetinib was designed around a fundamentally different pharmacologic strategy, termed Deep Cyclic Inhibition, or DCI, which uses a high free-drug peak to

H.C. Wainwright Starts Immuneering Corporation (IMRX) at Buy

Thu, 06 Aug 2026 06:06:48 -0400

H.C. Wainwright analyst Andres Maldonado initiates coverage on Immuneering Corporation (NASDAQ: IMRX) with a Buy rating and a price target of $14.00.
The analyst comments "What’s new? We are initiating coverage of Immuneering (IMRX) with a Buy rating and $14 PT based on a thesis that extends well beyond the 17.3-month median OS currently driving investor attention in pancreatic cancer. MEK was never an unimportant target, but chronic MEK inhibition has historically been a poor way to drug it. Atebimetinib was designed around a fundamentally different pharmacologic strategy, termed Deep Cyclic Inhibition, or DCI, which uses a high free-drug peak to

Immuneering Corporation (IMRX) Reports In-Line Q2 EPS

Wed, 05 Aug 2026 09:09:34 -0400

Immuneering Corporation (NASDAQ: IMRX) reported Q2 EPS of ($0.27), in-line with the analyst estimate of ($0.27).
For earnings history and earnings-related data on Immuneering Corporation (IMRX) click here.

Form 10-Q Immuneering Corp For: Jun 30

Wed, 05 Aug 2026 07:57:00 -0400
si-local-file:///var/storage/secattach/20260805/26870471.html

Form 10-Q Immuneering Corp For: Jun 30

Wed, 05 Aug 2026 07:57:00 -0400
si-local-file:///var/storage/secattach/20260805/26870471.html

Form 10-Q Immuneering Corp For: Jun 30

Wed, 05 Aug 2026 07:57:00 -0400
si-local-file:///var/storage/secattach/20260805/26870471.html

Form 10-Q Immuneering Corp For: Jun 30

Wed, 05 Aug 2026 07:57:00 -0400
si-local-file:///var/storage/secattach/20260805/26870471.html

Form 8-K Immuneering Corp For: Aug 05

Wed, 05 Aug 2026 07:41:00 -0400
si-local-file:///var/storage/secattach/20260805/26870372.html